EP0051593A1 - Isolation of carbohydrates from cell tissue - Google Patents

Isolation of carbohydrates from cell tissue

Info

Publication number
EP0051593A1
EP0051593A1 EP81900324A EP81900324A EP0051593A1 EP 0051593 A1 EP0051593 A1 EP 0051593A1 EP 81900324 A EP81900324 A EP 81900324A EP 81900324 A EP81900324 A EP 81900324A EP 0051593 A1 EP0051593 A1 EP 0051593A1
Authority
EP
European Patent Office
Prior art keywords
galp
process according
glc
gal
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP81900324A
Other languages
German (de)
French (fr)
Inventor
Sigfrid Edvin Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0051593A1 publication Critical patent/EP0051593A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells

Definitions

  • the present invention relates to a process of isolating from different types of cell tissue carbohydrates mainly consisting of oligosaccharides with degradation of glycoconjugates present in the cell tissue, said glycoconjugate being a common term for glycoproteins, proteoglycanes and glycolipids.
  • Cell tissue is a complex material consisting inter alia of so-called glycoconjugates, which are constituted by complex structures composed of carbohydrates, proteins and lipids.
  • the three main types of glycoconjugates are glycoproteins, proteoglycanates and glycolipids.
  • the carbohydrate chains are mostly N-glycosidically bound to asparagine or O-glycosidically to serine, treonine, hydroxylysine or hydr ⁇ xyproline.
  • the carbohydrate chains of the proteoglycanes have similar bonds to the protein part.
  • the carbohydrate part is O-glycosidically bound and is present as glycosyl ceramides in man and animals.
  • the carbohydrate part of cell membrane glycoconjugates has been found to play an essential role in several biological functions including cell-cell interactions, as receptors for antibodies, enzymes, hormones, viruses and toxines.
  • cell-cell interactions As receptors for antibodies, enzymes, hormones, viruses and toxines.
  • the present invention has for its purpose to provide a process for releasing the carbohydrate part from the glycoconjugates in cell tissue while maintaining the carbohydrate chains in a more or less intact state. More in particular, the invention provides for a process for isolating the carbohydrate fraction from glycolipids of cell tissue by specifically cleaving the glycosidic bond between the carbohydrate part and the ceramide residue.
  • the present invention is based on technique residing in treating the cell tissue with a reactant containing or consisting of trifluoroacetic acid anhydride.
  • a reactant containing or consisting of trifluoroacetic acid anhydride By this treatment, which can be termed trifluoroacetolysis, the oligosaccharide chains are released from both glycoproteins and glycolipids with simultaneous degradation of proteins and lipids, whereby the oligosaccharides in the form of their trifluoroacetates can be separated and recovered.
  • trifluoroacetic acid anhydride solely or trifluoroacetic acid anhydride in combination with trifluoroacetic acid, the latter constituting up to about 90 % by volume of the reactant mixture.
  • a preferred reactant is one wherein trifluoroacetic acid anhydride and trifluoroacetic acid are present in about equal proportions based on volume.
  • the treatment with the reactant is preferably carried out at an increased temperature and at an increased pressure.
  • a preferred temperature range is 80-110°C, for example about 100°C.
  • the overpressure in the latter case is about 4 atms.
  • the cell tissue is constituted by erytrocyte membranes from which can be recovered oligosaccharides possessing blood group specificity.
  • Such blood group specific oligosaccharides recovered in accordance with the technique of this invention can be coupled to carriers with antigenicity, and conjugates obtained thereby may then be used for immunisation for the purpose of obtaining specific antibodies.
  • An alternative use of isolated oligosaccharides is coupling of said saccharides to carriers for the preparation of immunosorbent columns which can be used. for purification and isolation of specific antibodies.
  • the specific antibodies made can be used in reactants for blood group determination and for other medicinal purposes.
  • the reaction mixture obtained when treating the cell tissue with the reactant is suitably evaporized to dryness, and the residue vaporization is distributed between water and a water-immiscible solvent, the aqueous phase containing the carbohydrate fraction being recovered and the solvent phase containing inter alia protein residues and lipid residues being discarded.
  • a water-immiscible solvent there may be used for example ether or methylene chloride.
  • the erytrocyte membranes are suitably homogenized and suspended in water, whereafter lyophilisation is carried out before the treatment with the reactant.
  • the oligosaccharides recovered by the process according to this invention may suitably be purified by gelchromatography and preparative paper chromatography. In this manner there may be obtained from blood of the blood group A the oligosaccharide: ⁇ -GalNAcp-(1-3)-Gal (A-tri) ⁇ -Galp-(1-4)- ⁇ -Galp-(1-4)-Glc or ⁇ -GalNAcp-(1-3)- ⁇ -Galp-(1-4)- ⁇ -Galp-(1-4)-Glc.
  • oligosaccharides mentioned under A- and B-blood are obtained from AB-blood.
  • the technique according to this invention namely release and recovery of oligosaccharides from erytrocyte membranes which show blood group specificity
  • four main steps are part of the procedure, namely the following: a. Isolation of blood group specific oligosaccharides from erytrocyte membranes; b. Chemical modification of isolated oligosaccharide for coupling to an antigenic carrier or a carrier for the preparation of immunosorbent.
  • d Purification of antibodies.
  • EXAMPLES a Preparation of oligosaccharides. Erytrocytes from discarded blood of blood groups A, B, AB and O are lysed and the membranes are isolated by means of centrifugation. In this way about 10 grams of membranes are obtained from one liter of blood. The membranes are treated according to the process of Dodge, J.T., Mitchell, C, and Hanahan, D.J. (1963),
  • reaction mixture is cooled and evaporized to dryness, there being obtained a dark to black-coloured residue.
  • residue there is added methanol (700 ml), and the mixture is evaporised to dryness.
  • the residue is then diluted with 50 % aqueous solution of acetic acid (1000 ml), and is allowed to star. ⁇ at room temperature for about l8 hours.
  • the reaction mixture is filtered with a glass filter and evaporised to dryness.
  • the residue obtained is distributed between water and diethyl ether.
  • the ether phase is washed 4 times with water, and the combined wash solutions are washed with diethyl ether 4 times.
  • the aqueous solution obtained is yellow-coloured and contains the released oligcsaccharides.
  • the oligosaccharides obtained are in such form that the N-acetyl functions have been converted to N-trifluoroacetyl groups.
  • the oligosaccharides obtained can be purified by gel chromatography followed by a preparative paper chromatography, and the purification procedure is continuously surveyed with gas chromatography mass spectrometry.
  • the following oligosaccharides are obtained in the present example by treatment of blood originating from blood groups A, B, AB and O with varying blood groups within the P-system:
  • Chemical modification of isolated oligosaccharides In order that the oligosaccharides shall be capable of coupling to carriers of different kinds they should be chemically modified. Such modification can be performed by means of known technique. Before the chemical modification it is suitable to de-N-trifluoroacetylate the oligosaccharides, which is suitably carried out in a basic environment at a pH of about 10-12 and at room temperatures for a period of time of about 20 hours. This results in the formation of amino groups, which can be N-acetylized to reform the N-acetyl functions.
  • the aliphatic amino groups formed by the de-N-trifluoroacetylation can be used for coupling the modified oligosaccharide to different carrier materials.
  • the modified oligosaccharides can be coupled to proteins, which can be constituted by albumen or edestine, and possibly to lipid A (from lipopolysaccharide) for the purpose of obtaining a high yield of M-antibodies.
  • the conjugates obtained are then used for immunising animals, for example rabbit or horse, or for the production of antibodies by hybridom technique (Kohler, G. and Milstein, C, 1975, Nature (London) 256, pp. 495-497; Kohler G., and Milstein, C, 1976, Eur.J. Immunol. 6 pp. 511-519).
  • the antisera thereby obtained are then serologically used in connection with known blood classification methods.
  • d Purification of antibodies.
  • Chemically modified blood group active oligosaccharides prepared according to the above are coupled to a suitable carrier material, for example Sephadex, and then sera from immunised animals are passed through an immunosorbent column formed by the treated Sephadex.
  • Antibodies having specificity vis-a-vis coupled oligosaccharide adheres by reaction with same, whereas materials of no interest are washed away.
  • the specific antibodies adhering to the column by reaction with coupled oligosaccharides are then desorbed, and antibody solutions of unambiguously defined specificity are obtained.
  • Purified specific antibodies ar ⁇ then tested for specificity for control and may then be used for blood group determination by hemagglutination technique.
  • the present invention is not delimited to the exemplary application for preparation of blood group active oligosaccharides from erytrocyte membranes as described above.
  • the invention is applicable to all types of cell tissue for recovery and isolation of oligosaccharides for different purposes.
  • epithelium tissue intestinal mucous membrane, urinary tract epithelium, lung epithelium etc.
  • isolated oligosaccharides can be of diagnostic importance.
  • GalNAcp 2-acetamido-2-deoxy-D-galactopyranosyl
  • Gal D-galactose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procede d'isolation de la fraction hydrates de carbone (oligosaccharides) a partir de tissus cellulaires avec degradation des glycoconjugues, le tissu cellulaire etant traite avec un reactif contenant ou se composant d'anhydride d'acide trifluoroacetique, les hydrates de carbone etant liberes a la suite de leur conversion en trifluoroacetates, qui sont facultativement detrifluoroacetyles. En partant de membranes erythrocytes, des oligosaccharides possedant une specificite de groupes sanguins peuvent etre recuperes, a partir de tels oligosaccharides et sont utiles pour la determination du groupe sanguin.Method for isolating the carbohydrate fraction (oligosaccharides) from cell tissues with degradation of the glycoconjugates, the cell tissue being treated with a reagent containing or consisting of trifluoroacetic acid anhydride, the carbohydrates being released to following their conversion to trifluoroacetates, which are optionally detrifluoroacetylated. Starting from erythrocyte membranes, oligosaccharides having blood group specificity can be recovered from such oligosaccharides and are useful for blood group determination.

Description

TITLE OF INVENTION;
ISOLATION OF CARBOHYDRATES FROM CELL TISSUE.
TECHNICAL FIELD;
The present invention relates to a process of isolating from different types of cell tissue carbohydrates mainly consisting of oligosaccharides with degradation of glycoconjugates present in the cell tissue, said glycoconjugate being a common term for glycoproteins, proteoglycanes and glycolipids. Cell tissue is a complex material consisting inter alia of so-called glycoconjugates, which are constituted by complex structures composed of carbohydrates, proteins and lipids. The three main types of glycoconjugates are glycoproteins, proteoglycanates and glycolipids. In the glycoproteins the carbohydrate chains are mostly N-glycosidically bound to asparagine or O-glycosidically to serine, treonine, hydroxylysine or hydrόxyproline. The carbohydrate chains of the proteoglycanes have similar bonds to the protein part. In the glycolipids, finally,the carbohydrate part is O-glycosidically bound and is present as glycosyl ceramides in man and animals.
BACKGROUND ART:
The carbohydrate part of cell membrane glycoconjugates has been found to play an essential role in several biological functions including cell-cell interactions, as receptors for antibodies, enzymes, hormones, viruses and toxines. In order to determine the structure and to study the biological activity of the carbohydrate part of glycoconjugates in cell membranes it is desirable to release the oligosaccharide chains in a form as intact as possible. Such a procedure would be preferred compared to the almost impossible task cf isolating glycoconjugates in a pure form. SUMMARY OF THE INVENTION;
Thus, the present invention has for its purpose to provide a process for releasing the carbohydrate part from the glycoconjugates in cell tissue while maintaining the carbohydrate chains in a more or less intact state. More in particular, the invention provides for a process for isolating the carbohydrate fraction from glycolipids of cell tissue by specifically cleaving the glycosidic bond between the carbohydrate part and the ceramide residue. Moreover, in another aspect of the invention, there is provided a process of isolating, from complex carbohydrate structures of cell tissue (glycolipids, proteoglycanes, and glycoprotein), oligosaccharides bound to a di-substituted 2-acetamido-2- deoxyhexose by specifically cleaving the 2-acetamido-2- deoxyhexosepyranosidic bond and then by elimination reactions releasing the pligosaccharide substituents.
The present invention is based on technique residing in treating the cell tissue with a reactant containing or consisting of trifluoroacetic acid anhydride. By this treatment, which can be termed trifluoroacetolysis, the oligosaccharide chains are released from both glycoproteins and glycolipids with simultaneous degradation of proteins and lipids, whereby the oligosaccharides in the form of their trifluoroacetates can be separated and recovered.
As a reactant for treating the cell tissue there may be used trifluoroacetic acid anhydride solely or trifluoroacetic acid anhydride in combination with trifluoroacetic acid, the latter constituting up to about 90 % by volume of the reactant mixture. A preferred reactant is one wherein trifluoroacetic acid anhydride and trifluoroacetic acid are present in about equal proportions based on volume. The treatment with the reactant is preferably carried out at an increased temperature and at an increased pressure. A preferred temperature range is 80-110°C, for example about 100°C. The overpressure in the latter case is about 4 atms.
In a preferred embodiment of the process according to the present invention the cell tissue is constituted by erytrocyte membranes from which can be recovered oligosaccharides possessing blood group specificity. Such blood group specific oligosaccharides recovered in accordance with the technique of this invention can be coupled to carriers with antigenicity, and conjugates obtained thereby may then be used for immunisation for the purpose of obtaining specific antibodies. An alternative use of isolated oligosaccharides is coupling of said saccharides to carriers for the preparation of immunosorbent columns which can be used. for purification and isolation of specific antibodies. The specific antibodies made can be used in reactants for blood group determination and for other medicinal purposes.
The reaction mixture obtained when treating the cell tissue with the reactant is suitably evaporized to dryness, and the residue vaporization is distributed between water and a water-immiscible solvent, the aqueous phase containing the carbohydrate fraction being recovered and the solvent phase containing inter alia protein residues and lipid residues being discarded. As a water-immiscible solvent there may be used for example ether or methylene chloride.
As a pretreatment for the trifluoroacetolysis the erytrocyte membranes are suitably homogenized and suspended in water, whereafter lyophilisation is carried out before the treatment with the reactant.
The oligosaccharides recovered by the process according to this invention may suitably be purified by gelchromatography and preparative paper chromatography. In this manner there may be obtained from blood of the blood group A the oligosaccharide: α-GalNAcp-(1-3)-Gal (A-tri) α-Galp-(1-4)-β-Galp-(1-4)-Glc or α-GalNAcp-(1-3)-α-Galp-(1-4)-β-Galp-(1-4)-Glc. From blood of the blood group B there is obtained in addition to the two last-mentioned instead of A-tri the oligosaccharide: α-Gal-(1-3)-Gal (B-tri) From blood of the blood group O there is obtained in the same manner the oligosaccharide: α-Fucp-(1-2)-Gal instead of A-tri.
All the oligosaccharides mentioned under A- and B-blood are obtained from AB-blood. With regard to the preferred application of the technique according to this invention, namely release and recovery of oligosaccharides from erytrocyte membranes which show blood group specificity, one may thus observe that up to the practical use four main steps are part of the procedure, namely the following: a. Isolation of blood group specific oligosaccharides from erytrocyte membranes; b. Chemical modification of isolated oligosaccharide for coupling to an antigenic carrier or a carrier for the preparation of immunosorbent. c. Immunisation of animals, alternatively preparation of antibodies by means of hybridom technique. d. Purification of antibodies.
The present invention will now be described by non-limiting examples which are based upon the preferred application of the invention for the preparation of oligosaccharides carrying blood group antigenicity from erytrocyte membranes.
EXAMPLES a. Preparation of oligosaccharides. Erytrocytes from discarded blood of blood groups A, B, AB and O are lysed and the membranes are isolated by means of centrifugation. In this way about 10 grams of membranes are obtained from one liter of blood. The membranes are treated according to the process of Dodge, J.T., Mitchell, C, and Hanahan, D.J. (1963),
Arch. Biochem. Biophys. 100, 119-130, i.e. homogenised, suspended in water and lyophilised.
To 50 grams of the lyophilised material there are added trifluoro acetic acid anhydride (1.25 liter) and trifluoro acetic acid (1.25 liter), and the reaction mixture is heated at about 100°C in a tube of acid resistant stainless steel at an overpressure of about 4 atms for a period of time of about 48 hours.
After this treatment the reaction mixture is cooled and evaporized to dryness, there being obtained a dark to black-coloured residue. To said residue there is added methanol (700 ml), and the mixture is evaporised to dryness. The residue is then diluted with 50 % aqueous solution of acetic acid (1000 ml), and is allowed to star.ά at room temperature for about l8 hours. The reaction mixture is filtered with a glass filter and evaporised to dryness.
The residue obtained is distributed between water and diethyl ether. The ether phase is washed 4 times with water, and the combined wash solutions are washed with diethyl ether 4 times. The aqueous solution obtained is yellow-coloured and contains the released oligcsaccharides.
The oligosaccharides obtained are in such form that the N-acetyl functions have been converted to N-trifluoroacetyl groups. The oligosaccharides obtained can be purified by gel chromatography followed by a preparative paper chromatography, and the purification procedure is continuously surveyed with gas chromatography mass spectrometry. The following oligosaccharides are obtained in the present example by treatment of blood originating from blood groups A, B, AB and O with varying blood groups within the P-system:
A-blood Speci- Yield, ficity mg/g membrane Oligosaccharide α-GalNAcp-(1-3)-Gal A 1 α-Fucp α-Galp-(1-4)-β-Galp-(1-4)-Glc pk 1 α-GalNAcp-(1-3)-α-Galp-(1-4)-β-Ga_p-(1-4)-Glc. P 10 (globoside)
B-blood α-Gal-(1-3)-Gal B 1
trihexoside p 1 globoside P 10 AB-blood
All stated under A-blood and B-blood.
O-blood α-Fucp-(1-2)-Gal O(H) 1 trihexoside p 1 globoside p 10 b. Chemical modification of isolated oligosaccharides. In order that the oligosaccharides shall be capable of coupling to carriers of different kinds they should be chemically modified. Such modification can be performed by means of known technique. Before the chemical modification it is suitable to de-N-trifluoroacetylate the oligosaccharides, which is suitably carried out in a basic environment at a pH of about 10-12 and at room temperatures for a period of time of about 20 hours. This results in the formation of amino groups, which can be N-acetylized to reform the N-acetyl functions.
The procedure for modifying isolated oligosaccharides is exemplified below for a B-active trisaccharide, namely α-Galp-(1-3)-[L-Fuep-(1-2)-)]-Gal diagrammatically in the following way: α-Galp-(1-3)-Gal 1. Acetylation α-Galp-(1-3)-β-Galp-OCH2CH2CH2NH2 2. HBr/AcOH 3. HOCH2CH2CH2NO2
L-Fucp (Koenigs-Knorr) L-Fucp 4. Hydrogenation The above reaction steps can be carried through with a total yield of at least about 50 %. The aliphatic amino groups formed by the de-N-trifluoroacetylation can be used for coupling the modified oligosaccharide to different carrier materials.
c. Immunisation of animals.
The modified oligosaccharides can be coupled to proteins, which can be constituted by albumen or edestine, and possibly to lipid A (from lipopolysaccharide) for the purpose of obtaining a high yield of M-antibodies. The conjugates obtained are then used for immunising animals, for example rabbit or horse, or for the production of antibodies by hybridom technique (Kohler, G. and Milstein, C, 1975, Nature (London) 256, pp. 495-497; Kohler G., and Milstein, C, 1976, Eur.J. Immunol. 6 pp. 511-519). The antisera thereby obtained are then serologically used in connection with known blood classification methods. d. Purification of antibodies.
Chemically modified blood group active oligosaccharides prepared according to the above are coupled to a suitable carrier material, for example Sephadex, and then sera from immunised animals are passed through an immunosorbent column formed by the treated Sephadex. Antibodies having specificity vis-a-vis coupled oligosaccharide adheres by reaction with same, whereas materials of no interest are washed away. The specific antibodies adhering to the column by reaction with coupled oligosaccharides are then desorbed, and antibody solutions of unambiguously defined specificity are obtained. Purified specific antibodies ar^ then tested for specificity for control and may then be used for blood group determination by hemagglutination technique.
It should be observed that the present invention is not delimited to the exemplary application for preparation of blood group active oligosaccharides from erytrocyte membranes as described above. The invention is applicable to all types of cell tissue for recovery and isolation of oligosaccharides for different purposes.
As further examples there may be mentioned epithelium tissue (intestinal mucous membrane, urinary tract epithelium, lung epithelium etc.), wherein isolated oligosaccharides can be of diagnostic importance.
In this disclosure the abbreviations used in the structural formulae have the following meaning: GalNAcp = 2-acetamido-2-deoxy-D-galactopyranosyl Gal = D-galactose
Fucp = 6-deoxy-L-galactose Galp = D-galactopyranosyl Glc = D-glucose

Claims

CLAIMS:
1. A process for isolating the carbohydrate fraction (oligosaccharides) from cell tissue with degradation of the glycoconjugates, characterized thereby that the cell tissue is treated with a reagent containing or consisting of trifluoroacetic acid anhydride, the carbohydrates being released under conversion to trifluoroacetates, which are optionally detrifluoroacetylized.
2. A process according to claim 1, characterized thereby that the treatment with the reagent is performed at an increased temperature and at an increased pressure, for example about 100°C and about 4 atms. overpressure.
3. A process according to claim 1 or 2, characterized thereby that the treatment is performed with a reagent consisting of trifluoroacetic acid anhydride and up to about 90 % by volume of trifluoroacetic acid.
4. A process according to any of the preceding claims, characterized thereby that the reaction mixture obtained by treatment of the cell tissue with the reactant is evaporized to dryness and that the evaporization residue is distributed between water and a water-immiscible solvent, the aqueous phase containing the carbohydrate fraction being recovered and the solvent phase being discarded.
5. A process according to any of the preceding claims, characterized thereby that the cell tissue is constituted by erytrocyte membranes, oligosaccharides being recovered which show blood group specificity.
6. A process according to claim 5, characterized thereby that the erytrocyte membranes are homogenized, suspended in water and lyophilized before the treatment with the reagent.
7. A process according to any of the preceding claims, characterized thereby that oligosaccharides recovered are purified by gel chromatography followed by paper chromatography.
8. A process according to claim 7, characterized thereby that starting from erytrocyte membranes from blood of the A-group there is obtained the oligosaccharide: α-GalNAcp-(1-3)-Gal α-Fucp α-Galp-(1-4)-β-Galp-(1-4)-Glc or α-GalNAcp-(1-3)-α-Galp-(1-4)-β-Galp-(1-4)-Glc.
9. A process according to claim 7, characterized thereby that starting from erytrocyte membranes from blood of the B-group there is obtained the oligosaccharide: α-Gal-(1-3)-Gal α-Fucp α-Galp-(1-4)-β-Galp-(1-4)-Glc or α-GalNAcp-(1-3)-α-Galp-(1-4)-β-Galp-(1-4)-Glc.
10. A process according to claim 7, characterized thereby that starting from erytrocyte membranes from blood of the O-group there is obtained the oligosaccharide: α-Fucp-(1-2)-Gal, α-Galp-(1-4)-β-Galp-(1-4)-Glc or α-GalNAcp-(1-3)-α-Galp-(1-4)-β-Galp-(1-4)-Glc.
11. A process according to claim 7, characterized thereby that starting from erytrocyte membranes from blood of the AB-group there Is obtained the oligo saccharide: α-GalNAcp-(1-3)-Gal α-Fucp, α-Gal-(1-3)-Gal α-Fucp α-Galp-(1-4)-β-Galp-(1-4)-Glc or α-GalNAcp-(1-3)-α-Galp-(1-4)-β-Galp-(1-4)-Glc.
EP81900324A 1980-01-28 1981-01-28 Isolation of carbohydrates from cell tissue Withdrawn EP0051593A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8000658A SE8000658L (en) 1980-01-28 1980-01-28 ISOLATION OF CARBON HYDRATES FROM CELL TISSUE
SE8000658 1980-01-28

Publications (1)

Publication Number Publication Date
EP0051593A1 true EP0051593A1 (en) 1982-05-19

Family

ID=20340092

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81900324A Withdrawn EP0051593A1 (en) 1980-01-28 1981-01-28 Isolation of carbohydrates from cell tissue

Country Status (6)

Country Link
EP (1) EP0051593A1 (en)
JP (1) JPS57500022A (en)
DK (1) DK427581A (en)
IT (1) IT1141962B (en)
SE (1) SE8000658L (en)
WO (1) WO1981002104A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2117789B (en) * 1982-03-29 1985-08-29 East Anglian Regional Health Abo blood grouping reagent
SE8301609D0 (en) * 1983-03-23 1983-03-23 Svenska Sockerfabriks Ab ASSOCIATION AND COMPOSITION OF THERAPEUTIC OR DIAGNOSTIC APPLICATION AS PROCEDURES FOR THERAPEUTIC TREATMENT
SE8304006D0 (en) * 1983-07-15 1983-07-15 Karlsson Karl Anders ASSOCIATION AND COMPOSITION OF THERAPEUTIC OR DIAGNOSTIC USE AND PROCEDURE FOR THERAPEUTIC TREATMENT
FR2553518B1 (en) * 1983-10-13 1986-04-18 Choay Sa NEW CONJUGATES DEVELOPED BY FIXING A LIGAND ON AN INSOLUBLE SUPPORT, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8102104A1 *

Also Published As

Publication number Publication date
IT8119379A0 (en) 1981-01-28
DK427581A (en) 1981-09-25
WO1981002104A1 (en) 1981-08-06
SE8000658L (en) 1981-07-29
IT1141962B (en) 1986-10-08
JPS57500022A (en) 1982-01-07

Similar Documents

Publication Publication Date Title
US4238473A (en) Artificial oligosaccharide antigenic determinants
Watkins et al. Further observations on the inhibition of blood‐group specific serological reactions by simple sugars of known structure
Stoll et al. Improved procedure for the construction of neoglycolipids having antigenic and lectin-binding activities, from reducing oligosaccharides
Barry Colominic acid, a polymer of N-acetylneuraminic acid
FI83659C (en) Process for the preparation of therapeutically useful O-glycoside compounds and intermediates
Rylatt et al. Autorosette inhibition factor: isolation and properties of the human plasma protein
McKenzie et al. Ia antigenic specificities are oligosaccharide in nature: hapten-inhibition studies.
JPS62502260A (en) antiviral agent
FR2509313A1 (en) 3-FUCOSYL-N-ACETYL LACTOSAMINE DERIVATIVES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
DE69737298T2 (en) CONJUGATES OF POLYSACCHARIDES AND BIOMOLECULES
Cox et al. Cell wall composition of two strains of Blastomyces dermatitidis exhibiting differences in virulence for mice
Lundblad Two urinary oligosaccharides characteristics of A1 and B secretors: Isolation and partial characterization
US4757003A (en) Method for the detection of cancer
Trotter et al. Chemical composition of the cell wall of Amoebidium parasiticum
Chatterjee et al. Synthesis of Neo glycoproteins containing the 3, 6-di-O-methyl-β-d-glucopyranosyl epitope and their use in serodiagnosis of leprosy
EP0089940A1 (en) Compositions for therapeutic or diagnostic use containing oligosaccharides
Coligan et al. A disaccharide hapten from streptococcal group C carbohydrate that cross-reacts with the Forssman glycolipid
EP0051593A1 (en) Isolation of carbohydrates from cell tissue
Stacey et al. The Polysaccharides of Mycobacterium Tuberculosis1
Gahmberg et al. Organization of glycoprotein and glycolipid in the plasma membrane of normal and transformed cells as revealed by galactose oxidase
Miller Podraza et al. Screening for the presence of polyglycosylceramides in various tissues: partial characterization of blood group-active complex glycosphingolipids of rabbit and dog small intestines
EP3221337A1 (en) Multivalent ligand-lipid constructs
Peczon et al. Intestinal basement membrane of Ascaris suum. Preparation, morphology, and composition
Carlsson et al. Structure of some oligosacharides derived from rat-intestinal glycoproteins
Morgan The Croonian Lecture A contribution to human biochemical genetics; the chemical basis of blood-group specificity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19811029

AK Designated contracting states

Designated state(s): DE FR GB NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19830531